STARTVerso 4 Phase III trial of faldaprevir plus peg interferon alfa-2a and ribavirin (PR) in patients with HIV and HCV genotype 1 coinfection: end of treatment response - Rockstroh, J; Nelson, M; Soriano, V; Arasteh, K
Paper presented at: AASLD The Liver Meeting; November 1–5, 2013; Washington, DC